Literature DB >> 20634005

Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Fang Xie1, Qin Wang, Yongjing Chen, Yongping Gu, Hui Mao, Wang Zeng, Xueguang Zhang.   

Abstract

OX40, a membrane-bound member of the tumor-necrosis-factor-receptor (TNFR) superfamily, plays an important role in proliferation, survival and infiltration of activated T cells via binding to OX40L. Recent studies indicate that OX40/OX40L system mediates the adhesion and infiltration of adult T cell leukemia (ATL). Previously, we detected OX40 expression in breast carcinoma cell lines and tissues. The correlation of expression of OX40 and OX40L and clinical features in breast carcinogenesis, however, has not been well characterized. The expression of OX40 and OX40L in 107 invasive ductal carcinomas (IDCa), 9 ductal carcinomas in situ (DCIS), and 31 fibroadenomas from breast tissues and its relationship with the clinical features were determined using immunohistochemistry (peroxidase-conjugated polymer method, ChemMate™ Envision™ Detection kit). The positive immunostaining rates for OX40 in IDCa, DCIS and fibroadenomas from breast tissues were 85.0%, 66.7% and 38.7% respectively, showing a significant difference in OX40 expression among IDCa, DCIS and fibroadenoma of breast (z=5.206, P=0.001). Increased staining intensity of OX40 was associated with TNM stages (z=2.112, P=0.017). Meanwhile, a relation of OX40 expression with lymph node metastatic status in IDCa was found (P=0.041). The expression of OX40L did not show any obvious difference among IDCa, DCIS and fibroadenomas from breast tissues. OX40L expression was also not related to histopathological parameters in IDCa except for progesterone receptor (PR) being positive (P=0.005). However, a high coincidental positive rate for OX40 and OX40L was observed in biopsy samples with IDCa (P=0.017, Kappa=0.231). The present results suggest that high OX40 expression may be associated with malignant transformation, progression, invasion and metastasis in breast cancer biology.
Copyright © 2010 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20634005     DOI: 10.1016/j.prp.2010.05.016

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  18 in total

1.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis.

Authors:  Srikanth Yellayi; Brendan Hilliard; Mustafa Ghazanfar; Akivaga Tsingalia; Michael H Nantz; Laura Bollinger; Fabian de Kok-Mercado; James G Hecker
Journal:  Mol Pharm       Date:  2011-07-19       Impact factor: 4.939

Review 3.  Immunotherapy for the treatment of breast cancer.

Authors:  Brenda Ernst; Karen S Anderson
Journal:  Curr Oncol Rep       Date:  2015-02       Impact factor: 5.075

4.  Identification of microenvironment related potential biomarkers of biochemical recurrence at 3 years after prostatectomy in prostate adenocarcinoma.

Authors:  Xiaoru Sun; Lu Wang; Hongkai Li; Chuandi Jin; Yuanyuan Yu; Lei Hou; Xinhui Liu; Yifan Yu; Ran Yan; Fuzhong Xue
Journal:  Aging (Albany NY)       Date:  2021-06-16       Impact factor: 5.682

5.  Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.

Authors:  Elizabeth D Pratico; Bruce A Sullenger; Smita K Nair
Journal:  Nucleic Acid Ther       Date:  2012-10-31       Impact factor: 5.486

6.  Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation.

Authors:  Alexander Pedroza-Gonzalez; Kangling Xu; Te-Chia Wu; Caroline Aspord; Sasha Tindle; Florentina Marches; Michael Gallegos; Elizabeth C Burton; Daniel Savino; Toshiyuki Hori; Yuetsu Tanaka; Sandra Zurawski; Gerard Zurawski; Laura Bover; Yong-Jun Liu; Jacques Banchereau; A Karolina Palucka
Journal:  J Exp Med       Date:  2011-02-21       Impact factor: 14.307

Review 7.  New Immunotherapy Strategies in Breast Cancer.

Authors:  Lin-Yu Yu; Jie Tang; Cong-Min Zhang; Wen-Jing Zeng; Han Yan; Mu-Peng Li; Xiao-Ping Chen
Journal:  Int J Environ Res Public Health       Date:  2017-01-12       Impact factor: 3.390

8.  B7-H3 promotes gastric cancer cell migration and invasion.

Authors:  Yecheng Li; Xiaodong Yang; Yong Wu; Kui Zhao; Zhenyu Ye; Junjia Zhu; Xiaohui Xu; Xin Zhao; Chungen Xing
Journal:  Oncotarget       Date:  2017-05-13

9.  CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.

Authors:  Ha Zhu; Yan Gu; Yiquan Xue; Ming Yuan; Xuetao Cao; Qiuyan Liu
Journal:  Oncotarget       Date:  2017-12-07

10.  Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.

Authors:  Tingting Zhou; Di Xu; Bufu Tang; Yanling Ren; Yiru Han; Gege Liang; Jing Wang; Ling Wang
Journal:  Anticancer Drugs       Date:  2018-10       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.